Alembic Pharmaceuticals Ltd. on Thursday said it has received a final approval from the US health regulator for its generic version of Paroxetine extended-release tablets indicated for treatment of depression and anxiety.
The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Paroxetine extended-release tablets of strengths 25 mg and 37.5 mg, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the reference listed drug product, Paxil CR extended-release tablets, 25 mg and 37.5 mg, of Apotex Inc, it added.
The Paroxetine extended-release tablets 25 mg and 37.5 mg, are indicated for treatment of major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder, the company said.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.